I. J. Amanna, I. Messaoudi, and M. K. Slifka, Protective immunity following vaccination: How is it defined?, Human Vaccines, vol.4, issue.4, pp.316-319, 2008.
DOI : 10.4161/hv.4.4.5751

URL : http://www.tandfonline.com/doi/pdf/10.4161/hv.4.4.5751?needAccess=true

D. H. Barouch, J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira et al., Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys, Nature, vol.86, pp.224-228
DOI : 10.1128/JVI.00644-12

T. Bradley, A. Trama, N. Tumba, E. Gray, X. Lu et al., Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity, EBioMedicine, vol.12, pp.196-207
DOI : 10.1016/j.ebiom.2016.08.045

D. Candotti, D. Costagliola, C. Joberty, O. Bonduelle, C. Rouzioux et al., Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism, Journal of Medical Virology, vol.15, issue.3, pp.256-263, 1999.
DOI : 10.1093/infdis/173.1.60

P. Carotenuto, D. Looij, L. Keldermans, F. De-wolf, and J. Goudsmit, Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection, AIDS, vol.12, issue.13, pp.1591-1600, 1998.
DOI : 10.1097/00002030-199813000-00005

M. Caskey, F. Klein, J. C. Lorenzi, M. S. Seaman, W. Jr et al., Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117, Nature, vol.14, issue.7557, pp.487-491, 2015.
DOI : 10.1101/gr.849004

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890714

D. Cecilia, C. Kleeberger, A. Muñoz, J. V. Giorgi, and S. Zolla-pazner, A Longitudinal Study of Neutralizing Antibodies and Disease Progression in HIV???1???Infected Subjects, The Journal of Infectious Diseases, vol.179, issue.6, pp.1365-1374, 1999.
DOI : 10.1086/314773

A. Chaillon, M. Braibant, S. Hué, S. Bencharif, D. Enard et al., Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection, PLoS ONE, vol.7, issue.8, p.44163, 2012.
DOI : 10.1371/journal.pone.0044163.t004

W. C. Cheung, S. A. Beausoleil, X. Zhang, S. Sato, S. M. Schieferl et al., A proteomics approach for the identification and cloning of monoclonal antibodies from serum, Nature Biotechnology, vol.82, issue.5, pp.447-452, 2012.
DOI : 10.1073/pnas.92.16.7297

N. A. Doria-rose, R. M. Klein, M. G. Daniels, S. O-'dell, M. Nason et al., Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables, Journal of Virology, vol.84, issue.3, pp.1631-1636, 2010.
DOI : 10.1128/JVI.01482-09

B. Emu, E. Sinclair, D. Favre, W. J. Moretto, P. Hsue et al., Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment, Journal of Virology, vol.79, issue.22, pp.14169-14178, 2005.
DOI : 10.1128/JVI.79.22.14169-14178.2005

Z. Euler, M. J. Van-gils, E. M. Bunnik, P. Phung, B. Schweighardt et al., Cross???Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression, The Journal of Infectious Diseases, vol.201, issue.7, pp.1045-1053, 2010.
DOI : 10.1086/651144

URL : https://academic.oup.com/jid/article-pdf/201/7/1045/18061264/201-7-1045.pdf

N. T. Freund, H. Wang, L. Scharf, L. Nogueira, J. A. Horwitz et al., Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller, Science Translational Medicine, vol.60, issue.373, 2017.
DOI : 10.2144/000113370

S. A. Gallo, C. M. Finnegan, M. Viard, Y. Raviv, A. Dimitrov et al., The HIV Env-mediated fusion reaction, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1614, issue.1, pp.36-50, 2003.
DOI : 10.1016/S0005-2736(03)00161-5

URL : http://doi.org/10.1016/s0005-2736(03)00161-5

M. J. Van-gils, E. M. Bunnik, J. A. Burger, Y. Jacob, B. Schweighardt et al., Rapid Escape from Preserved Cross-Reactive Neutralizing Humoral Immunity without Loss of Viral Fitness in HIV-1-Infected Progressors and Long-Term Nonprogressors, Journal of Virology, vol.84, issue.7, pp.3576-3585, 2010.
DOI : 10.1128/JVI.02622-09

S. Grabar, H. Selinger-leneman, S. Abgrall, G. Pialoux, L. Weiss et al., Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV, AIDS, vol.23, issue.9, pp.1163-1169, 1999.
DOI : 10.1097/QAD.0b013e32832b44c8

L. Heyndrickx, A. Heath, E. Sheik-khalil, J. Alcami, V. Bongertz et al., International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II, PLoS ONE, vol.139, issue.5, p.36438, 2012.
DOI : 10.1371/journal.pone.0036438.s006

V. Holl, S. Hemmerter, R. Burrer, S. Schmidt, A. Bohbot et al., Involvement of Fc??R I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages, The Journal of Immunology, vol.173, issue.10, pp.6274-6283, 2004.
DOI : 10.4049/jimmunol.173.10.6274

V. Holl, M. Peressin, T. Decoville, S. Schmidt, S. Zolla-pazner et al., Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic Cells, Journal of Virology, vol.80, issue.12, pp.6177-6181, 2006.
DOI : 10.1128/JVI.02625-05

URL : http://jvi.asm.org/content/80/12/6177.full.pdf

P. Hraber, M. S. Seaman, R. T. Bailer, J. R. Mascola, D. C. Montefiori et al., Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection, AIDS, vol.28, issue.2, pp.163-169, 2014.
DOI : 10.1097/QAD.0000000000000106

N. Imami, S. J. Westrop, N. Grageda, and A. A. Herasimtschuk, Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses, Frontiers in Immunology, vol.4, p.58, 2013.
DOI : 10.3389/fimmu.2013.00058

URL : http://journal.frontiersin.org/article/10.3389/fimmu.2013.00058/pdf

A. F. Labrijn, P. Poignard, A. Raja, M. B. Zwick, K. Delgado et al., Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1, Journal of Virology, vol.77, issue.19, pp.10557-10565, 2003.
DOI : 10.1128/JVI.77.19.10557-10565.2003

C. G. Lange, M. M. Lederman, J. S. Madero, K. Medvik, R. Asaad et al., Impact of Suppression of Viral Replication by Highly Active Antiretroviral Therapy on Immune Function and Phenotype in Chronic HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.30, issue.1, 2002.
DOI : 10.1097/00042560-200205010-00005

C. Lécuroux, A. Sáez-cirión, I. Girault, P. Versmisse, F. Boufassa et al., Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8+ T Cell Response in HIV Controllers, Journal of Virology, vol.88, issue.1, pp.176-187, 2014.
DOI : 10.1128/JVI.02098-13

A. Lederle, B. Su, V. Holl, J. Penichon, S. Schmidt et al., Neutralizing Antibodies Inhibit HIV-1 Infection of Plasmacytoid Dendritic Cells by an Fc??RIIa Independent Mechanism and Do Not Diminish Cytokines Production, Scientific Reports, vol.75, issue.1, p.5845, 2014.
DOI : 10.1128/JVI.75.11.5421-5424.2001

J. H. Lee, G. Ozorowski, and A. B. Ward, Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer, Science, vol.53, issue.3, pp.1043-1048, 2016.
DOI : 10.1016/0304-3991(94)90038-8

G. K. Lewis, A. L. Devico, and R. C. Gallo, Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development, Proceedings of the National Academy of Sciences, vol.88, issue.13, pp.15614-15621, 2014.
DOI : 10.1128/JVI.00728-14

URL : http://www.pnas.org/content/111/44/15614.full.pdf

J. Liu, K. Ghneim, D. Sok, W. J. Bosche, Y. Li et al., Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus, Science, vol.73, issue.6303, pp.1045-1049
DOI : 10.1038/nm833

C. L. Lu, D. K. Murakowski, S. Bournazos, T. Schoofs, D. Sarkar et al., Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo, Science, vol.274, issue.5289, pp.1001-1004, 2016.
DOI : 10.1126/science.274.5289.985

M. Magierowska, I. Theodorou, P. Debré, F. Sanson, B. Autran et al., Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-in- fected individuals, Blood, vol.93, pp.936-941, 1999.

V. Martinez, D. Costagliola, O. Bonduelle, N. N-'go, A. Schnuriger et al., Combination of HIV???1???Specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long???Term Nonprogression, The Journal of Infectious Diseases, vol.191, issue.12, pp.2053-2063, 2005.
DOI : 10.1086/430320

A. C. Mcneil, W. L. Shupert, C. A. Iyasere, C. W. Hallahan, J. A. Mican et al., High-level HIV-1 viremia suppresses viral antigen-specific CD4+ T cell proliferation, Proc. Natl. Acad. Sci. U. S. A. 98, pp.13878-13883, 2001.
DOI : 10.1126/science.277.5322.112

S. A. Migueles and M. Connors, Success and failure of the cellular immune response against HIV-1, Nature Immunology, vol.72, issue.6, pp.563-570, 2015.
DOI : 10.1126/science.1237874

I. Mikell, D. N. Sather, S. A. Kalams, M. Altfeld, G. Alter et al., Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1, PLoS Pathogens, vol.21, issue.1, 2011.
DOI : 10.1371/journal.ppat.1001251.s004

M. Pancera, T. Zhou, A. Druz, I. S. Georgiev, C. Soto et al., Structure and immune recognition of trimeric pre-fusion HIV-1 Env, Nature, vol.208, issue.7523, pp.455-461
DOI : 10.1084/jem.20101907

L. G. Perez, M. R. Costa, C. A. Todd, B. F. Haynes, and D. C. Montefiori, Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41, Journal of Virology, vol.83, issue.15, pp.7397-7410, 2009.
DOI : 10.1128/JVI.00656-09

L. G. Perez, S. Zolla-pazner, and D. C. Montefiori, Antibody-DEPENDENT, Fc?RI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis, 2013.

C. Petitdemange, A. Achour, S. Dispinseri, I. Malet, A. Sennepin et al., A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion, Clinical Infectious Diseases, vol.57, issue.5, pp.745-755, 2013.
DOI : 10.1093/cid/cit335

A. Piantadosi, D. Panteleeff, C. A. Blish, J. M. Baeten, W. Jaoko et al., Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression, Journal of Virology, vol.83, issue.19, pp.10269-10274, 2009.
DOI : 10.1128/JVI.01149-09

V. Potard, Z. Ait-arkoub, H. Agut, and . Group, Polymorphism of gp41 glycoprotein might influence the progression to disease in HIV-1 infection, AIDS, vol.27, issue.7, pp.1189-1191, 2013.
DOI : 10.1097/QAD.0b013e32835f6b30

H. Ruppach, P. Nara, I. Raudonat, Z. Elanjikal, H. Rübsamen-waigmann et al., Human Immunodeficiency Virus (HIV)-Positive Sera Obtained Shortly after Seroconversion Neutralize Autologous HIV Type 1 Isolates on Primary Macrophages but Not on Lymphocytes, Journal of Virology, vol.74, issue.12, pp.5403-5411, 2000.
DOI : 10.1128/JVI.74.12.5403-5411.2000

URL : http://jvi.asm.org/content/74/12/5403.full.pdf

S. Sadanand, T. J. Suscovich, and G. Alter, Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design, Annual Review of Medicine, vol.67, issue.1, pp.185-200, 2016.
DOI : 10.1146/annurev-med-091014-090749

A. Sáez-cirión, C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia et al., HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype, Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group Proc. Natl. Acad. Sci. U. S. A. 104, pp.6776-6781, 2007.
DOI : 10.1002/biot.200600045

K. E. Stephenson and D. H. Barouch, Broadly Neutralizing Antibodies for HIV Eradication, Current HIV/AIDS Reports, vol.211, issue.236, pp.31-37, 2016.
DOI : 10.1084/jem.20141050

URL : https://link.springer.com/content/pdf/10.1007%2Fs11904-016-0299-7.pdf

B. Su and C. Moog, Which Antibody Functions are Important for an HIV Vaccine?, Frontiers in Immunology, vol.10, issue.Suppl 2, p.289, 2014.
DOI : 10.1186/1479-5876-10-144

URL : http://journal.frontiersin.org/article/10.3389/fimmu.2014.00289/pdf

V. Vieillard, J. L. Strominger, and P. Debré, NK cytotoxicity against CD4+ T cells during HIV-1 infection: A gp41 peptide induces the expression of an NKp44 ligand, Proceedings of the National Academy of Sciences, vol.387, issue.6631, pp.10981-10986, 2005.
DOI : 10.1038/387426a0

V. Vieillard, D. Costagliola, A. Simon, and P. Debré, Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection, AIDS, vol.20, issue.14, pp.1795-1804, 2006.
DOI : 10.1097/01.aids.0000244198.65263.17

URL : http://pdfs.journals.lww.com/aidsonline/2006/09110/Specific_adaptive_humoral_response_against_a_gp41.2.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1503338647285;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzdN2ziiHhY6wPF9tfA80junpwhe3BgTIW8MAzFJzgZ93A=;hash|Z2aLQFRoC/qrTuZXWIgAkw==

V. Vieillard, R. Le-grand, J. Dausset, and P. Debré, A vaccine strategy against AIDS: An HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques, Proceedings of the National Academy of Sciences, vol.80, issue.1, pp.2100-2104, 2008.
DOI : 10.1128/JVI.80.1.236-245.2006

V. Vieillard, N. Dereuddre-bosquet, I. Mangeot-méderlé, R. Le-grand, and P. Debré, An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques, Vaccine, vol.30, issue.48, pp.6883-6891, 2012.
DOI : 10.1016/j.vaccine.2012.09.004

V. Vieillard, S. Gharakhanian, O. Lucar, C. Katlama, O. Launay et al., Perspectives for immunotherapy: which applications might achieve an HIV functional cure?, Oncotarget, vol.7, issue.25, pp.38946-38958, 2016.
DOI : 10.18632/oncotarget.7793

URL : https://hal.archives-ouvertes.fr/hal-01285657

W. Jr, A. P. Scharf, L. Scheid, J. F. Klein, F. Bjorkman et al., Structural insights on the role of antibodies in HIV-1 vaccine and therapy, Cell, vol.156, pp.633-648, 2014.

E. J. Wherry, V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech et al., Lineage relationship and protective immunity of memory CD8 T cell subsets, Nature Immunology, vol.4, issue.3, pp.225-234, 2003.
DOI : 10.1038/ni889

Y. Wine, D. R. Boutz, J. J. Lavinder, A. E. Miklos, R. A. Hughes et al., Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response, Proc. Natl. Acad. Sci. U. S. A. 110, pp.2993-2998, 2013.
DOI : 10.1074/mcp.M900540-MCP200

R. Wyatt and J. Sodroski, The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens, Science, vol.280, issue.5371, pp.1884-1888, 1998.
DOI : 10.1126/science.280.5371.1884

J. Xie, W. Lu, A. Samri, A. Schnuriger, B. C. Da-silva et al., ALT-ANRS-CO15 study group, 2010. Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control, AIDS, vol.24, pp.2323-2329

J. L. Xu and M. M. Davis, Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities, Immunity, vol.13, issue.1, pp.37-45, 2000.
DOI : 10.1016/S1074-7613(00)00006-6

L. Yu and Y. Guan, Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1, Frontiers in Immunology, vol.340, issue.Suppl, p.250, 2014.
DOI : 10.1126/science.1234150

URL : http://journal.frontiersin.org/article/10.3389/fimmu.2014.00250/pdf

W. Zhuge, F. Jia, I. Adany, O. Narayan, and E. B. Stephens, Plasmas from Lymphocyte- and Macrophage-Tropic SIVmac-Infected Macaques Have Antibodies with a Broader Spectrum of Virus Neutralization Activity in Macrophage versus Lymphocyte Cultures, Virology, vol.227, issue.1, pp.24-33, 1997.
DOI : 10.1006/viro.1996.8300